S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study

S Banerjee, S Singhal, V Shah,R Van Vollenhoven, M Pike,E Morand,I Catlett, VP Werth,JT Merrill,N Delev, C Hobar,B Sharkey, T Wegman

Lupus Science and Medicine（2022）

Cited 0|Views0

No score

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined